A Study of ICP-192 in Patients With Advanced Solid Tumors

Status unconfirmed · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma

In brief

This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase I), dose escalation and Part II (Phase II), dose expansion.

Key facts

Study ID
NCT04565275
Run by
Beijing InnoCare Pharma Tech Co., Ltd.
People needed
45
Starts
2021-02-01
Expected to finish
2024-04-15
Last updated by the study team
2023-03-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.